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Abstract
Aims/hypothesis There is limited evidence on how multifac-
torial treatment improves outcomes of diabetes when initi-
ated in the lead time between detection by screening and
diagnosis in routine clinical practice. Cardiac autonomic
neuropathy (CAN) in people with diabetes indicates wide-
spread damage to the autonomic nervous system, which
may severely affect health and quality of life. We examined
effects of early detection and subsequent intensive treatment
of type 2 diabetes in primary care on the prevalence of CAN
at the 6-year follow-up examination in a pragmatic cluster-
randomised parallel group trial.
Methods One hundred and ninety general practices were rand-
omised to deliver either intensive multifactorial treatment (IT)
or routine care (RC) as recommended by national guidelines to
patients with type 2 diabetes, identified through a stepwise
screening programme in the primary care setting. 1533 people
(IT, n0910; RC, n0623) were identified and included. At the
6-year follow-up examination, measures of CAN were applied
in an unselected subsample of 777 participants using heart rate
variability analysis and standard tests of CAN.
Results At the 6-year follow-up examination, the prevalence
of early CAN was 15.1% in the RC group and 15.5% in the
IT group, while manifest CAN was present in 7.1% and
7.3%, respectively. We found no statistically significant
effect of intensive treatment on the prevalence of CAN
compared with routine care.
Conclusions/interpretation In the Danish arm of the
ADDITIONStudy, signs ofCANwere highly prevalent 6 years
after a screening-based diagnosis of type 2 diabetes. Intensive
multifactorial treatment did not significantly affect the preva-
lence of CAN compared with routine care. However, at follow-
up the level of medication was also high in the RC group.
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Introduction
Screening for diabetes is advocated in many countries.
However, there is limited evidence that benefit estimates
obtained in studies of clinically detected type 2 diabetes
also apply to screen-detected populations. Cardiac autonom-
ic neuropathy (CAN) in patients with diabetes is associated
with an increased mortality risk compared with patients with
diabetes and no signs of CAN, but it remains an overlooked
complication of diabetes, and the prevalence among people
with screen-detected diabetes is unknown [1]. Furthermore,
there is limited trial evidence on prevention of CAN. The
Steno-2 Trial showed that, in patients with longstanding
type 2 diabetes, intensive multifactorial intervention can
reduce the risk of developing CAN by 68%, while there
was no reduction in the risk of diabetic peripheral neurop-
athy (DPN) [2].
The multicentre Anglo–Danish–Dutch Study of Intensive
Treatment In People with Screen-Detected Diabetes in
Primary Care (ADDITION) Trial was the first trial to study
the effect of early detection of type 2 diabetes in general
practice followed by intensive multifactorial treatment
based on the treatment principles of the Steno-2 Trial [3].
In a previous analysis, we found that intensive multifactorial
treatment led to a statistically non-significant reduction in
the prevalence of DPN compared with routine care as rec-
ommended by national guidelines [4].
In this paper we aim to describe the effect of early
detection and consecutive routine care or intensive multi-
factorial treatment on the prevalence of CAN in patients
with screen-detected type 2 diabetes at the 6-year follow-
up examination.
Methods
Design The design and rationale of the ADDITION Study
(ClinicalTrials.gov NCT00237549) have been reported [5]. In
brief, ADDITION-Denmark consists of two phases: (1) a
screening phase; and (2) a pragmatic, cluster-randomised par-
allel group trial. In five regions of Denmark, 190 general
practices were randomised to screening plus routine care of
diabetes (RC) or screening followed by intensive multifacto-
rial treatment (IT). Randomisation was stratified by region and
the number of full-time general practitioners per practice.
A population-based stepwise screening programme
among people aged 40–69 years without known diabetes
was undertaken in each practice, and individuals were diag-
nosed with diabetes according to WHO criteria, as previ-
ously described [6]. Overall, 1533 (623 RC, 910 IT) eligible
participants with screen-detected diabetes agreed to take
part in the trial. After an average of 5.9 years of follow-up,
1278 participants were re-examined (512 RC, 766 IT). Of
these, 108 were only seen by their own general practitioner.
Examinations for CAN were performed in three of the test
centres (863 participants; 339 RC, 524 IT). Sixty-four par-
ticipants attending one of these centres were not tested for
CAN. Reasons for missing measurements were: station clo-
sure because of insufficient staff or unavailable testing de-
vice (n042); atrial fibrillation or pacemaker (n014);
disability preventing testing (n03). Of a total of 799 partic-
ipants tested for CAN, 22 had missing values on at least two
of the three standard CAN tests mentioned below, and 76
had a missing value in one of three. Most missing values
were due to difficulties in complying with the strain pressure
in the Valsalva manoeuvre or with rising from the supine
position to standing. As two abnormal tests are sufficient for
a diagnosis of CAN [7], we chose to include all participants
with at least two complete tests, yielding a study sample of
777 participants in this analysis. Electronic supplementary
material (ESM) Fig. 1 displays the practice and participant
flow.
Intervention The specific characteristics of the interventions
to promote intensive treatment have been described previ-
ously in detail [5]. The purpose of the intensive treatment
was to provide the best possible evidence-based treatment in
primary care. We aimed to educate and support general
practitioners and practice nurses in target-driven manage-
ment (using medication and promotion of a healthy lifestyle)
of hyperglycaemia, blood pressure and cholesterol, based on
the stepwise regimen used in the Steno-2 Study [2].
Intensive treatment was promoted through the addition of
several features to existing diabetes care. Practice staff were
provided with educational materials for patients, and
patients were sent reminders if annual check-up appoint-
ments were overdue. Practices received additional funding
to support the delivery of the extra care added to the usual
care/consultations. All treatment targets and algorithms
were based on evidence from randomised controlled trials
demonstrating the benefits of intensive treatment of cardio-
vascular risk factors in people with type 2 diabetes [3] and
are displayed in ESM Table 1. Family physicians were
advised to consider prescribing ACE inhibitors or angioten-
sin II antagonists for patients who had a blood pressure of
120/80 mmHg or higher, and 75 mg aspirin daily for
patients who had no specific contraindications. After publi-
cation of the Heart Protection Study, we altered the treat-
ment algorithm to recommend prescription of a statin for all
patients with a cholesterol concentration of 3.5 mmol/l or
higher at any time. Although treatment targets were prespe-
cified and classes of medication recommended, decisions on
prescriptions, including the choice of individual drugs, were
made by practitioners and patients.
In the RC group, general practitioners were only provid-
ed with diagnostic test results and patients received the
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standard pattern of diabetes care according to Danish na-
tional recommendations [8, 9].
Measurements Health assessments at baseline and follow-
up included biochemical, anthropometric and questionnaire
measures, and were undertaken by centrally trained staff
unaware of study group allocation following standard oper-
ating procedures. Blood pressure was calculated as the mean
of three measurements performed after at least a 10 min rest,
using Omron blood pressure recorders. Height and weight
were measured in light indoor clothing, without shoes, using
a fixed rigid stadiometer and a Tanita scale, respectively.
Biochemical measurements were performed at Aarhus
University Hospital and Steno Diabetes Centre, Gentofte at
baseline and follow-up, respectively. The specific analyses
have been described previously [6].
At the 6-year follow-up examination, heart rate variabil-
ity (HRV) on supine rest and standard tests of CAN were
performed: after 10 min of supine resting, a 2 min ECG
recording was made in all participants to obtain HRV. The
beat-to-beat intervals in this 2 min ECG recording were
analysed by normal statistical descriptions (time domain)
and by estimating frequency-specific fluctuations in HRV
(frequency domain) [10]. In the time domain, the root mean
square of the sum of the squares of differences between
consecutive R–R intervals and standard deviation of
normal-to-normal intervals were calculated. In the frequen-
cy domain, we calculated the power in the low-frequency
(0.04–0.15 Hz) and high-frequency (0.15–0.4 Hz) band.
These measures were included, as they can provide early
additional information on both sympathetic and parasympa-
thetic modulation [11].
Participants were subsequently tested with three standard
CAN tests [12].
(1) Lying to standing (30/15). The participant was asked to
quickly rise from the supine to the standing position as
the ECG was continuously recorded, and the ratio
between the shortest R–R interval (around the 15th
heartbeat after the rise) and the longest R–R interval
(around the 30th heartbeat) was calculated [13]. A
ratio with age-dependent cut-off levels was used:
age <30 years, 1.15; age 30–39 and 40–49 years,
1.07; age 50–59 years, 1.05; age 60–69 years, 1.02;
age 70–79 years, 1.00 [12, 14].
(2) Deep breathing for 1 min with a respiration frequency
of six breaths/min to examine the exhalation/inhalation
ratio (E:I ratio) [13]. The E:I ratio was expressed as the
mean of the longest R–R interval during each inhala-
tion divided by the mean of the shortest R–R interval
during each exhalation. Age-dependent cut-off levels
were used for the E:I ratio: age <30 years, 1.24; age
30–39 years, 1.19; age 40–49 years, 1.15; age 50–
59 years, 1.11; age 60–69 years, 1.08; age 70–79 years,
1.05 [12, 14].
(3) Valsalva manoeuvre [13] to determine the ratio of
maximum and minimum R–R interval during forced
expiration in 15 s against a fixed resistance and 45 s of
normal breathing. Age-dependent cut-off levels were
used: age <30 years, 1.42; age 30–39 years, 1.35; age
40–49 years, 1.29; age 50–59 years, 1.24; age 60–
69 years, 1.19; age 70–79 years, 1.15 [12, 14].
Consumption of food and caffeine-containing beverages
and smoking were prohibited for 2 h before laboratory
testing. All laboratory tests for CAN were performed be-
tween 08:00 and 13:00 hours in a quiet and isolated exam-
ination room. HRV and the cardiovascular reflex tests were
performed by technicians using a Vagus device (Medicus
Engineering, Aarhus, Denmark) [15]. This device automat-
ically records an ECG signal, with a sampling frequency of
1,000 Hz, from which heart rate and HRV are calculated.
CAN was defined using the ADA criteria and the Toronto
Consensus Panel on Diabetic Neuropathy as follows: CAN
0, all tests are normal; CAN early, one test is abnormal
signifying the presence of possible or early stage CAN;
CAN manifest, two or three abnormal tests signifying def-
inite or late stage CAN [12, 16].
Standardised self-report questionnaires were used to col-
lect information on sociodemographic characteristics (edu-
cation, employment and ethnicity), lifestyle habits (smoking
status, alcohol consumption) and self-reported cardiovascu-
lar disease (previous myocardial infarction, stroke or oper-
ation/instrumentation on the heart).
Statistical analysis Patient characteristics at baseline and
follow-up are presented as unadjusted means, or in the case
of skewed distributions as medians. Participants with miss-
ing values were compared with participants without missing
values. The prevalence data for each treatment group of
CAN were calculated as number of people with abnormal
tests divided by number of people who participated in the
test and had complete data from at least two CAN tests. Data
are presented with 95% CIs. The median values of the CAN
tests and the time and frequency measures were compared
between treatment groups. HRV ordinal logistic regression
was used to estimate the OR and 95% CI for the comparison
of the IT group with the RC group. The outcome measure
was presence of any degree of CAN. The standard errors
were adjusted to allow for intracluster correlation, where the
clusters were the general practices, using the ‘cluster()’
option in Stata. Interaction by sex, age, baseline HbA1c,
total cholesterol and systolic blood pressure was examined
with linear interaction terms between the treatment alloca-
tion and quartiles of each of these variables (except for sex).
The effect of the intervention, expressed as an OR, is
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presented stratified by the treatment target recommended at
trial initiation (HbA1c <7% [53 mmol/mol], total cholesterol
<5 mmol/l, and systolic blood pressure ≤135 mmHg), sex
and age (below/above 60 years). Sensitivity analyses were
performed, excluding patients using β blockers and patients
who reported regular or frequent hypoglycaemia. Statistical
analyses were performed with Stata (version 11, StataCorp
LP, College Station, TX, USA).
Results
Baseline characteristics are shown in Table 1. The average
follow-up time was 5.8 and 5.9 years for the RC and IT
groups, respectively. Median HbA1c did not change over the
follow-up period in either group, but there was a similar
decline in systolic blood pressure and total cholesterol in
both groups. The number of smokers substantially declined
in both groups with no difference between groups. Total
alcohol consumption also declined. There was no change in
BMI from baseline.
Patient characteristics including medication of participants
at follow-up are summarised in ESM Table 2. There was an
overall increase in the proportion of participants using medi-
cation during the follow-up. In the RC group, the proportion
taking antihypertensive drugs had increased from 40% to 76%
at follow-up, while the proportion taking lipid-lowering drugs
had increased from 20% to 81%. In the IT group, the
corresponding findings were increases from 38% to 82%
and 22% to 85%. At follow-up, antiglycaemic drugs were
taken by 52% in the RC group and 63% in the IT group.
Compared with the analysed population, patients with one
missing value on CAN tests were older (66.2 years) and in-
cluded more smokers. Patients with missing values on two or
more tests (n022) were older (68.4 years), more were smokers,
and their mean BMI was higher. The prevalence of abnormal
CAN tests at the follow-up examination, mean values from
each test, and median values from the time and frequency
domain measures are presented in Table 2 for both groups.
In Fig. 1, the effects of intervention expressed as ORs are
presented for the entire study sample and for subgroups. Tests
for interaction showed no statistically significant interaction
between treatment group (RC/IT) and sex, age, baseline
HbA1c, baseline total cholesterol and systolic blood pressure.
β blockers and hypoglycaemia are known to affect HRV.
However, exclusion of patients taking β blockers or those
who reported episodes of hypoglycaemia did not substan-
tially change the results.
Discussion
We found no overall effect of intensive multifactorial treat-
ment in general practice, delivered through education and
Table 1 Characteristics at
baseline of participants in the
Danish arm of ADDITION
who had two complete
CAN tests
Data are mean (SD) unless
otherwise indicated
aMedian (25th; 75th percentile)
IFCC, International Federation
of Clinical Chemistry and
Laboratory Medicine
Characteristic Routine care Intensive treatment
Patients, n 311 466
Male, n (%) 178 (57%) 287 (62%)
Age (years) 59.3 (6.6) 59.2 (6.8)
HbA1c
a (DCCT, %) 6.4 (6.0; 6.9) 6.4 (6.0; 7.1)
HbA1c
a (IFCC, mmol/mol) 46 (42; 52) 46 (42; 54)
Systolic blood pressure (mmHg) 147.1 (18.3) 147.1 (18.3)
Diastolic blood pressure (mmHg) 89.0 (11.1) 88.0 (10.1)
Weight (kg) (F;M) F 83.0 (16.8); M 94.4 (18.1) F 83.5 (16.5); M 94.7 (17.2)
Height (cm) (F;M) F 163.3 (5.5); M 175.9 (8.9) F 163.7 (6.0); M 176.1 (8.8)
BMI (kg/m2) (F;M) F 31.1 (5.8); M 30.5 (5.4) F 31.1 (5.9); M 30.5 (5.1)
Total cholesterol (mmol/l) 5.69 (1.10) 5.59 (1.06)
HDL-cholesterol (mmol/l) 1.38 (0.32) 1.35 (0.36)
Triacylglycerol (mmol/l)a 1.60 (1.10; 2.40) 1.60 (1.16; 2.20)
Smoking daily, n (%) 92 (30%) 137 (30%)
Alcohol (units per week)a 7 (2, 14) 7 (2, 16)
Microalbuminuria, n (%) 36 (13%) 52 (13%)
Macroalbuminuria, n (%) 2 (1%) 8 (2%)
Antihypertensive drugs, n (%) 123 (40%) 171 (38%)
ACE inhibitors or ATII blockers 59 (19%) 82 (18%)
β blockers 50 (16%) 82 (18%)
Lipid-lowering drugs, n (%) 59 (19%) 103 (22%)
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support of general practitioners and practice nurses in
evidence-based target-driven management and strict treat-
ment targets/algorithms, on the prevalence of CAN com-
pared with routine care delivered according to national
recommendations. However, at the 6-year follow-up ex-
amination, participants in both treatment groups in the
Danish arm of the ADDITION Trial were overall very
well treated. Our study found that, 6 years after a
screening-based diagnosis of diabetes, more than one in
seven patients had evidence of early CAN and one in 14
had manifest CAN.
The reported prevalence of CAN in other studies varies
considerably according to the diagnostic criteria, assessment
modalities and patient selection of each study [12]. In the
DiaCAN multicentre study, 524 patients were examined
using spectral analyses and predefined CAN tests; 22.1%
had definite CAN (three abnormal tests out of six tests),
while 12.2% had borderline CAN, defined as two abnormal
tests [17]. A study including patients from an outpatient
diabetes clinic reported a prevalence of 44.3% among 400
patients with type 2 diabetes when four CAN standard tests
were used [18]. Hence, it is not straightforward to compare
prevalences with our study. However, it is important to
emphasise that our findings show that, even in this group
of well-treated patients at an early stage of type 2 diabetes,
signs of CAN are present in a sufficiently large proportion to
warrant clinical attention. CAN is related to overall mortal-
ity. In a meta-analysis, the relative risk of overall mortality
associated with CAN was 2.14 (95% CI 1.83, 2.51) [1], and,
in a study on asymptomatic diabetic patients, cardiac auto-
nomic dysfunction had the strongest association with the
primary events (i.e. cardiac death and non-fatal myocardial
infarction) [19]. Furthermore, based on findings from the
ACCORD (Action to Control Cardiovascular Risk in
Diabetes) and VADT (Veterans Affairs Diabetes Trial) stud-
ies, it has been speculated that diabetic patients with CAN
may represent a group where intensive treatment and strict
treatment targets could pose a serious risk [20]. In our study,
nearly a quarter of the participants had either early or man-
ifest CAN 6 years after screen-detected diabetes diagnosis.
Table 2 At the 6-year follow-up examination, comparison of prevalence (% of examined population) of abnormal CAN tests and measures of HRV
in the RC and IT group in the Danish cohort of the ADDITION Study
Variable n (RC/IT) RC IT p value
CAN 0 243/356 77.9 (73.2, 82.5) 77.2 (73.4, 81.0) 0.69
CAN early 47/72 15.1 (11.1, 19.1) 15.5 (12.2, 18.8)
CAN manifest 22/34 7.1 (4.2, 9.9) 7.3 (4.9, 9.7)
Lying to standing (30/15) 1.14 (1.06; 1.23) 1.13 (1.06; 1.22) 0.43
E:I ratio 1.15 (1.10; 1.22) 1.15 (1.09; 1.23) 0.65
Valsalva manoeuvre 1.46 (1.27; 1.68) 1.45 (1.27; 1.65) 0.39
HRV
SDNN (ms) 27.7 (19.1; 39.8) 26.8 (19.6; 39.3) 0.52
RMSSD (ms) 17.6 (11.3; 30.1) 17.2 (10.55; 27.0) 0.28
aLF (ms2) 58.3 (23.8; 139.7) 59.1 (25.2; 123.0) 0.75
aHF (ms2) 37.3 (14.2; 101.0) 31.3 (12.5; 86.7) 0.25
Heart rate 72.4 (12.6) 72.3 (12.7) 0.87
Prevalences are presented with 95% CI, and the rest of the values are presented as median (25th; 75th percentile), except heart rate (mean and
standard deviation).
HF, high-frequency band; LF, low-frequency band; RMSSD, root mean square of the sum of the squares of differences between consecutive R–R
intervals ; SDNN, standard deviation from normal to normal intervals
Fig. 1 Effect of intensive multifactorial care in general practice on
presence of at least one abnormal CAN test at 6-year follow-up
examination compared with routine care expressed as OR (95% CI)
taking cluster effect into account. The effect is presented for the entire
study sample and for subgroups stratified by sex, baseline values for
age, HbA1c, systolic blood pressure (Sys BP) and total cholesterol
(Chol). To convert values for HbA1c in % into mmol/mol, subtract
2.15 and multiply by 10.929
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Therefore testing patients for CAN early in the course of
diabetes could potentially supply the clinician with im-
portant information on prognosis and treatment. Likewise,
in an earlier analysis of the ADDITION-Denmark Study,
we found that 34.8% in the RC group and 30.1% in the
IT group had signs of DPN at the follow-up examination
[4]. This confirms that diabetic neuropathy is indeed
prevalent among patients in the early stages of type 2
diabetes.
Several risk factors for the development of neuropathy
exist [1, 18, 21–23]. However, trial evidence of treatment to
prevent the development of CAN in people with type 2
diabetes is sparse [1, 12, 24]. The most salient lesson on
prevention of CAN derives from the Steno-2 Study. In the
Steno-2 study, intensive multifactorial treatment led to a
69% reduction in the risk of developing CAN after 7.8 years
of follow-up [2], and therefore a multifactorial approach is
suggested as the most beneficial [1].
The treatment strategy in the ADDITION Study was a
multifactorial, pharmacological and non-pharmacological
intervention and was inspired by the strategy used in the
Steno-2 Study. However, we found no difference in preva-
lence of CAN between treatment groups in our study. First,
during the follow-up period there was in general and among
clinicians a great focus on the treatment of diabetes in
Denmark, as the national treatment guidelines were revised
in accordance with the results of the Steno-2 Study [8, 9].
This also led to a substantial improvement in treatment in
the RC group. Hence, at follow-up, the two treatment
groups were almost equally well treated. We previously
speculated that clinicians in the study may use a threshold
approach with regard to the prescription of drugs [25]. As
the clinicians in the IT group were educated and supported
in target-driven patient management, they may have used a
lower threshold for prescription than those in the RC group,
especially at the beginning of the study when there were no
clearly stated national treatment targets for cholesterol and
HbA1c to guide RC practitioners. We performed subgroup
analyses to explore this threshold hypothesis by testing
whether the effect of intensive treatment was present in
specific subgroups of patients. However, we found no sub-
group effect of age, sex and baseline values of systolic blood
pressure, HbA1c or total cholesterol. Hence, we did not find
any patient group that might have benefitted additionally
from the intensive treatment.
Second, in the Steno-2 Study, the intensively treated
patients were managed by a small team of investigators
following specific guidelines, whereas patients were treated
in many different general practices in the ADDITION Study.
Consequently, adherence to guidelines was lower in the
ADDITION Study [3]. Third, patients included in the
Steno-2 Study had longstanding diabetes and microalbumi-
nuria at inclusion, and they were followed for a longer
period. The longer diabetes duration, the longer duration
of the study, and the fact that all patients in the Steno-2
Study already had complications at entry all contribute to
the higher prevalence of CAN, while the lower prevalence
in our study would make it more difficult to observe a
difference between the groups even if there was a true
treatment effect.
The overall null result of our study may imply that the
predisposition to develop diabetic neuropathy in the early
stages of diabetes is driven by pathophysiological mecha-
nisms operating earlier in life. On the other hand, consider-
ing the early diabetes diagnosis in our participants, we may
simply have been dealing with too small a time window to
detect any differences.
There are very limited data on the prevalence and pre-
vention of CAN in patients with screen-detected type 2
diabetes. ADDITION-Europe was the first international
study on the effects of early detection and intensive treat-
ment of type 2 diabetes. As CAN was only assessed in a
subsample of the Danish arm of the trial, this study is
unique. All patients were identified and treated in primary
care, and the trained staff, who were blinded to the treatment
allocation, used broadly accepted and standardised methods
for diagnosis. Our study therefore provides an up-to-date
and well-documented estimate of the prevalence of CAN in
a population with screen-detected diabetes. However, our
study is based on a population of white Northern European
patients, and one cannot readily generalise these findings to
a broader diabetes population. It is possible that different
prevalences and treatment effects are applicable in other
populations. We did not test for postural fall in blood pres-
sure, which is now recommended as a CAN test. However,
an abnormal orthostatic hypotension test result generally
occurs late in diabetes and subsequent to abnormalities in
heart rate tests [12]. As the study population in the
ADDITION Study is a well-treated population with a recent
diabetes diagnosis, we think it is acceptable to assume that
only a minority of the patients included would have an
abnormal orthostatic hypotension test.
We did not control for respiration during supine rest.
However, we only used the time and frequency domain
measures to compare the two treatment groups.
The patients excluded from the analyses because of
missing values were older and more of them were smok-
ers; the reported prevalences may therefore not reflect
the true prevalences. The number of patients in the IT
group was larger than in the RC group, even though
there were no differences in the number and types of
practices in the two groups. The practices were rando-
mised before screening and inclusion of patients, but it
seems that the intervention allocation enhanced the focus
on screening and thereby inclusion of patients in the IT
practices. However, the patient characteristics at baseline
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were not substantially different between the two treat-
ment groups; therefore we think that it is reasonable to
assume the prevalence of CAN at baseline was equally
distributed among the randomisation groups. The
reported prevalence differences can therefore be inter-
preted as differences in cumulative incidence during the
follow-up period.
To conclude, signs of CAN were highly prevalent in a
well-treated population with screen-detected type 2 dia-
betes. The prevalence of CAN was not reduced by edu-
cation and support of general practitioners and practice
nurses in evidence-based target-driven management and
treatment targets/algorithms compared with routine care
according to national guidelines, but at follow-up the
participants in the two treatment groups were equally
well treated.
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